FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis

BACKGROUND: FOLFOX chemotherapy is one of the most commonly used treatments for colorectal cancer (CRC) patients. However, the efficacy and tolerance of FOLFOX therapy varies between patients. The purpose of this study was to explore hub genes associated with primary chemotherapy-resistance and to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiyi, Sun, Lijun, Wang, Xiaojie, Sun, Yanwu, Chen, Ying, Xu, Meifang, Chi, Pan, Lu, Xingrong, Xu, Zongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078371/
https://www.ncbi.nlm.nih.gov/pubmed/32218799
http://dx.doi.org/10.3389/fgene.2020.00113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078371/
https://www.ncbi.nlm.nih.gov/pubmed/32218799
http://dx.doi.org/10.3389/fgene.2020.00113

Ejemplares similares